Alan J. Tiefenbrunn

Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 through 1999

William J. Rogers, John G. Canto, Costas T. Lambrew et al. · Journal of the American College of Cardiology · 2000 · 658 citations

Percutaneous Coronary Intervention, Cardiovascular Disease, Health Policy +10

Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction.

William J. Rogers, Laura J. Bowlby, Nisha C. Chandra et al. · Circulation · 1994 · 476 citations

Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial.

D Collen, Eric J. Topol, Alan J. Tiefenbrunn et al. · Circulation · 1984 · 385 citations · Full text

Fibrinogen Level, Placebo-controlled Trial, Coronary Artery Disease +18

The Volume of Primary Angioplasty Procedures and Survival after Acute Myocardial Infarction

John G. Canto, Nathan R. Every, David J. Magid et al. · New England Journal of Medicine · 2000 · 379 citations · Full text

Coronary Thrombolysis with Tissue-Type Plasminogen Activator in Patients with Evolving Myocardial Infarction

Frans Van de Werf, Philip A. Ludbrook, Steven R. Bergmann et al. · New England Journal of Medicine · 1984 · 361 citations

Pharmacotherapy, Biomedical Engineering, Coronary Artery Disease +16